RQC for the Prevention of Alzheimer's Disease and Retinal Amyloid-β (NCT06470061)
A Randomized Phase II Study to Evaluate Oral RQC for the Prevention of Alzheimer's Disease and Retinal Amyloid-β
🩺 Plain-English Summary (8th-Grade Level)
The goal of this clinical trial is to evaluate whether oral resveratrol, quercetin, and curcumin (RQC) can prevent the accumulation of retinal amyloid-β and/or cognitive decline over 24 months in adults aged 50-90 with Stage 1 or 2 Alzheimer's disease as described in FDA-2013-D-0077. The trial will also evaluate the safety and tolerability of RQC. Curcumin, which binds to amyloid-β, will act as a fluorescent label to identify retinal amyloid-β in vivo using optical coherence tomography (OCT)-autofluorescence imaging. The investigators will longitudinally evaluate the effect of RQC on retinal amyloid-β load cognitive outcomes including the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) and the Mini Mental State Examination (MMSE), and potential microvascular biomarkers. The investigators will also evaluate associations between retinal amyloid-β and progression to early Alzheimer's disease (mild cognitive impairment). The investigators will compare RQC, taken daily for 24 months, with curcumin alone, taken only during the 7 days preceding each of the six study visits to see if RQC can prevent (or reduce) amyloid-β and prevent the onset of mild cognitive impairment.
Who can join: Review the eligibility criteria below.
Location: Zaparackas & Knepper Ltd. — Chicago, Illinois
Age range: 50 Years to 90 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Zaparackas & Knepper Ltd. — Chicago, Illinois
📞 Contact the Study Coordinator
Phone: (312) 337-1285
Email: knezap@sbcglobal.net
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Alzheimer Disease
- The Use of Memantine for Prevention of Alzheimer's Disease — Charlottesville, Virginia
- Investigation of Inflammation Using [C-11]-CS1P1 — St Louis, Missouri
- Sleep Disturbance and Emotion Regulation Brain Dysfunction as Mechanisms of Neuropsychiatric Symptoms in Alzheimer's Dementia — Palo Alto, California
- A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study) — Gilbert, Arizona
- High Frequency Light and Sound Stimulation to Improve Brain Functions in Alzheimer's Disease — Cambridge, Massachusetts
- A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease — Phoenix, Arizona
Explore by condition: All Alzheimer Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.